Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC

In order to seek high-efficiency, low-toxicity anti-angiogenic drugs, Jiangsu Hengrui Medical Co., Ltd has developed an efficient VEGFR2 tyrosine kinase inhibitor (TKI) - Apatinib. This drug works mainly by inhibiting VEGFR2 to produce the anti-angiogenic effects and treat malignant tumors. Apatinib was shown to have good tumor growth-inhibiting activity against lung cancer in both in vivo and in vitro experiments. This study aims to further validate the efficacy and safety of Apatinib combined with chemotherapeutics in the treatment of advanced EGFR wild-type non-squamous, non-small-cell lung cancer.